Literature DB >> 18078773

Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.

B Winchester, D Bali, O A Bodamer, C Caillaud, E Christensen, A Cooper, E Cupler, M Deschauer, K Fumić, M Jackson, P Kishnani, L Lacerda, J Ledvinová, A Lugowska, Z Lukacs, I Maire, H Mandel, E Mengel, W Müller-Felber, M Piraud, A Reuser, T Rupar, I Sinigerska, M Szlago, F Verheijen, O P van Diggelen, B Wuyts, E Zakharova, J Keutzer.   

Abstract

Pompe disease is an autosomal recessive disorder of glycogen metabolism caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). It presents at any age, with variable rates of progression ranging from a rapidly progressive course, often fatal by one-year of age, to a more slowly, but nevertheless relentlessly progressive course, resulting in significant morbidity and premature mortality. In infants, early initiation of enzyme replacement therapy is needed to gain the maximum therapeutic benefit, underscoring the need for early diagnosis. Several new methods for measuring GAA activity have been developed. The Pompe Disease Diagnostic Working Group met to review data generated using the new methods, and to establish a consensus regarding the application of the methods for the laboratory diagnosis of Pompe disease. Skin fibroblasts and muscle biopsy have traditionally been the samples of choice for measuring GAA activity. However, new methods using blood samples are rapidly becoming adopted because of their speed and convenience. Measuring GAA activity in blood samples should be performed under acidic conditions (pH 3.8-4.0), using up to 2 mM of the synthetic substrate 4-methylumbelliferyl-alpha-D-glucoside or glycogen (50 mg/mL), in the presence of acarbose (3-9 microM) to inhibit the isoenzyme maltase-glucoamylase. The activity of a reference enzyme should also be measured to confirm the quality of the sample. A second test should be done to support the diagnosis of Pompe disease until a program for external quality assurance and proficiency testing of the enzymatic diagnosis in blood is established.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18078773     DOI: 10.1016/j.ymgme.2007.09.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  29 in total

1.  Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates.

Authors:  O P van Diggelen; L F Oemardien; N A M E van der Beek; M A Kroos; H K Wind; Y V Voznyi; D Burke; M Jackson; B G Winchester; A J J Reuser
Journal:  J Inherit Metab Dis       Date:  2009-04-19       Impact factor: 4.982

2.  Molecular diagnosis of German patients with late-onset glycogen storage disease type II.

Authors:  P R Joshi; D Gläser; S Schmidt; M Vorgerd; M Winterholler; K Eger; S Zierz; M Deschauer
Journal:  J Inherit Metab Dis       Date:  2008-07-10       Impact factor: 4.982

3.  Bioinformatic and biochemical studies point to AAGR-1 as the ortholog of human acid alpha-glucosidase in Caenorhabditis elegans.

Authors:  Jakub Sikora; Jana Urinovská; Filip Majer; Helena Poupetová; Jitka Hlavatá; Marta Kostrouchová; Jana Ledvinová; Martin Hrebícek
Journal:  Mol Cell Biochem       Date:  2010-03-27       Impact factor: 3.396

Review 4.  Diagnostic tools in late onset Pompe disease (LOPD).

Authors:  Olimpia Musumeci; Antonio Toscano
Journal:  Ann Transl Med       Date:  2019-07

Review 5.  Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases.

Authors:  Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

Review 6.  Genetics and metabolic cardiomyopathies.

Authors:  E C Wicks; P M Elliott
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

7.  Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases.

Authors:  Victoria Manwaring; Helen Prunty; Katie Bainbridge; Derek Burke; Niamh Finnegan; Rebecca Franses; Amanda Lam; Ashok Vellodi; Simon Heales
Journal:  J Inherit Metab Dis       Date:  2011-06-18       Impact factor: 4.982

8.  High-throughput assay of 9 lysosomal enzymes for newborn screening.

Authors:  Zdenek Spacil; Haribabu Tatipaka; Mariana Barcenas; C Ronald Scott; Frantisek Turecek; Michael H Gelb
Journal:  Clin Chem       Date:  2013-01-11       Impact factor: 8.327

9.  Pompe's Disease in Childhood: A Metabolic Myopathy.

Authors:  U Raju; S C Shaw; K S Rana; M Sharma; H R Ramamurthy
Journal:  Med J Armed Forces India       Date:  2011-07-21

10.  PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease.

Authors:  Marloes L C Hagemans; Rolinda L Stigter; Carine I van Capelle; Nadine A M E van der Beek; Leon P F Winkel; Laura van Vliet; Wim C J Hop; Arnold J J Reuser; Auke Beishuizen; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2010-01-27       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.